A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Public ClinicalTrials.gov record NCT06360354. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Study identification
- NCT ID
- NCT06360354
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 120 participants
Conditions and interventions
Interventions
- Anvumetostat Drug
- Gemcitabine Drug
- Nab-paclitaxel Drug
- Modified FOLFIRINOX Drug
- RMC-6236 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2024 (Actual)
- Primary completion
- Oct 31, 2026 (Estimated)
- Completion
- Nov 30, 2026 (Estimated)
- Last update posted
- Jun 1, 2026
2024 – 2026
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Duarte | California | 91010 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Translational Research in Oncology US Inc, Trio Central Pharmacy | Los Angeles | California | 90095 | — |
| University of California Los Angeles | Santa Monica | California | 90404 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| Hartford Hospital | Hartford | Connecticut | 06106 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Norwalk Hospital | Norwalk | Connecticut | 06856 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| University of Nebraska | Omaha | Nebraska | 68198 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| United States Oncology Regulatory Affairs Corporate Office | Nashville | Tennessee | 37203 | — |
| Oncology Consultants Cancer Center | Houston | Texas | 77030 | — |
| US Oncology Research Investigational Products Center | Irving | Texas | 75063 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22903 | — |
| Virginia Cancer Specialists PC | Fairfax | Virginia | 22031 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98106 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
| Northwest Cancer Specialists - Vancouver | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06360354, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06360354 live on ClinicalTrials.gov.